In an interim analysis of a Phase 2 trial.

Argos’ Arcelis immunotherapy reduces viral load in interim evaluation of Phase 2 HIV trial Argos Therapeutics today announced that, in an interim analysis of a Phase 2 trial, it is Arcelis immunotherapy directed at HIV, AGS-004, demonstrated a significant reduction in viral load and a delay in viral rebound kinetics during a 12-week antiretroviral treatment interruption when compared to pre-ART viral loads. The info shall be presented within an oral poster demonstration session. ART represents a major breakthrough for the management of HIV-infected sufferers, but isn’t without unwanted effects and is a life-long commitment cialis generique france tadalafilenfrance.com . Therapeutic immunotherapies to improve immune response and control viral replication are needed to limit contact with ART.

Arrowhead seeks acceptance to start out ARC-520 phase 2a trial for chronic hepatitis B infection Arrowhead Research Company , a biopharmaceutical organization developing targeted RNAi therapeutics, today announced that it lately filed a credit card applicatoin for approval to begin a stage 2a clinical trial of its RNAi-based therapeutic candidate, ARC-520, for the potential treatment of chronic hepatitis B virus disease. Pending approval, Arrowhead intends to proceed with a multicenter, randomized, double-blind, placebo-controlled, dose-escalation study.